Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy

Clinical and Experimental Hypertension

Volumn 36, Issue 4, 2014, Pages 244-250

  Oshikawa, Jin ^a   Toya, Yoshiyuki ^a   Morita, Satoshi ^b   Taguri, Masataka ^b   Hanaoka, Kazushige ^c   Hasegawa, Toshio ^d   Kaizu, Kazo ^e   Kamata, Kouju ^f   Kobayashi, Shuzo ^g   Ohtake, Takayasu ^g   Sato, Takeo ^h   Yasuda, Gen ^b   Kimura, Kenjiro ⁱ   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Kanagawa Prefectural Shiomidai Hospital   (Japan)

^e Yokohama Central Hospital   (Japan)

^f KITASATO UNIVERSITY   (Japan)

^g SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

^h Kawasaki City Tama Hospital   (Japan)

ⁱ ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor antagonists; Combination; Comparative study; Drug therapy; Hypertension; Sodium chloride symporter inhibitors

Indexed keywords

AMLODIPINE; CANDESARTAN; ELECTROLYTE; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; TELMISARTAN; URIC ACID; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL; AGED; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 84901842330     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.810227     Document Type: Article

References (33)

1. Mancia G, De Backer G, Dominiczak A, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
2. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
3. Yoshimura M, Kawai M. Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin- angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 2010;11:124-6.
4. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed dose combination therapy. Arch Intern Med 1996;156:1969-78.
5. Smink PA, Bakker SJ, Laverman GD, et al. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials. J Hypertens 2012;30:1022-8.
6. Dang A, Zhang Y, Liu G, et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 2006;20:45-50.
7. Würzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60.
8. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21:1157-62.
9. Dahlöf B. Management of cardiovascular risk with RAS inhibitor/ CCB combination therapy. J Hum Hypertens 2009;23:77-85.
10. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427.
11. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53: 982-92.
12. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
13. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73:1303-9.
14. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Human Hypertens 2011;25:346-53.
15. Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/ hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res 2007;30:831-7.
16. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009;32:962-8.
17. Kario K. Proposal of RAS-diuretic vs. RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure. J Am Soc Hypertens 2010;4:215-18.
18. Katsuya T, Ishikawa K, Sugimoto K, et al. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 2003;26:521-5.
19. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997;350:1734-7.
20. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009;54:716-23.
21. Kato J, Yokota N, Tamaki N, et al. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension. Hypertens Res 2011;34:331-5.
22. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81.
23. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28.
24. Slagman MC, Navis G, Laverman GD. Reversible effects of diuretics added to renin-angiotensin-aldosterone system blockade: impact on interpretation of long-term kidney function outcome. Am J Kidney Dis 2010;56:601-2.
25. Ishimitsu T, Ohno E, Nakano N, et al. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease. Clin Exp Hypertens 2011;33:366-72.
26. Kita T, Yokota N, Ichiki Y, et al. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res 2010;33:320-5.
27. Iwanaga T, Sato M, Maeda T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007;320:211-17.
28. Naritomi H, Fujita T, Ito S, et al. Efficacy and safety of long-term losartan therapy demonstrated by a propective observational study in Japanese patients with hypertension: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study. Hypertens Res 2008;31:295-304.
29. Ohshiro K, Sakima A, Nakada S, et al. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/ hydrochlorothiazide on uric acid metabolism in hypertensive patients. Clin Exp Hypertens 2011;33:565-70.
30. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep 2007;7: 191-9.
31. Fukuda M, Kimura G. Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 2006;29:645-53.
32. Aksnes TA, Reims HM, Guptha S, et al. Improved insulin sensitivity with the angiotensin II receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006;20:860-6.
33. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011;25:346-53.